Rasashram Pharma Laboratries Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-07-2024
- Paid Up Capital ₹ 2.93 M
as on 17-07-2024
- Company Age 23 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 17-07-2024
- Revenue 7.59%
(FY 2023)
- Profit -5.71%
(FY 2023)
- Ebitda 5.47%
(FY 2023)
- Net Worth 9.79%
(FY 2023)
- Total Assets 19.94%
(FY 2023)
About Rasashram Pharma Laboratries
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.93 M.
The company currently has active open charges totaling ₹4.00 M.
Raj Vyas, Arjun Vyas, Kishan Vyas, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24231GJ2001PTC039906
- Company No.
039906
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Dist Rajkot, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Rasashram Pharma Laboratries Private Limited offer?
Rasashram Pharma Laboratries Private Limited offers a wide range of products and services, including Diabetic Herbal Medicine, Diabetic Herbal Tablets & Capsules.
Who are the key members and board of directors at Rasashram Pharma Laboratries?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raj Vyas  | Director | 07-Jan-2012 | Current |
| Arjun Vyas | Director | 15-Apr-2002 | Current |
| Kishan Vyas | Director | 15-Apr-2002 | Current |
| Yogeshkumar Vyas | Director | 23-Aug-2001 | Current |
| Nareshkumar Vyas | Director | 23-Aug-2001 | Current |
| Sudhirkumar Vyas | Director | 23-Aug-2001 | Current |
Financial Performance of Rasashram Pharma Laboratries.
Rasashram Pharma Laboratries Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.59% increase. The company also saw a slight decrease in profitability, with a 5.71% decrease in profit. The company's net worth moved up by a moderate rise of 9.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rasashram Pharma Laboratries?
In 2023, Rasashram Pharma Laboratries had a promoter holding of 57.28% and a public holding of 42.72%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 31 Dec 2013 | ₹4.00 M | Open |
How Many Employees Work at Rasashram Pharma Laboratries?
Unlock and access historical data on people associated with Rasashram Pharma Laboratries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rasashram Pharma Laboratries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rasashram Pharma Laboratries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
